# 3 Aminopropoxyaryl derivatives, their preparation and pharmaceutical compositions containing them.

## Abstract
The compounds of the type having an

## Claims
1. An adrenergic blocking agent of the type having anEMI18.1 side chain attached through the l oxgen atom thereof directly to a heterocyclic nucleus, in free form or in salt form, characterized in that the heterocyclic nucleus comprises an N carbonylisoindolinyl radical and the l oxygen atom of the side chain is attached directly to the 4 position of the isoindolinyl ring. 2. A compound having the formula IEMI18.2 whereinR1 is alkyl of 3 to 7 carbon atoms or a groupEMI18.3 whereinA is alkyl of 2 to 5 carbon atoms X is a bond an oxygen or a sulfur atom, either R3 is hydrogen, halogen of atomic number of from 9 to 35, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms or hydroxy, and R4 is hydrogen and, when R3 is halogen of atomic number of from 9 to 35, R4 additionally may be halogen of atomic number of from 9 to 35 and, when R3 is alkoxy of 1 to 4 carbon atoms, R4 additionally may be alkoxy of 1 to 4 carbon atoms, or R3 and R4 together are methylenedioxy or ethylene dioxy, in the 2,3 or the 3,4 position, R5 is hydrogen and, when R3 and R4 both are alkoxy of 1 to 4 carbon atoms, R5 additionally may be alkoxy of 1 to 4 carbon atoms, with the proviso that X is separated by at least 2 carbon atoms from the nitrogen atom of the 3 amino propoxy side chain, andR2 is hydrogen, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms or phenyl unsubstituted or monosubstituted or independently disubstituted by alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, or halogen of atomic number of from 9 to 35, and physiologically acceptable hydrolyzable derivatives thereof having the hydroxy group in the 2 position of the 3 aminopropoxy side chain in esterified form, in free form or in salt form. 3. A compound of claim 2 of formula Ip,EMI20.1 wherein PR1 is alkyl of 3 to 7 carbon atoms or a group EMI20.2 whereinA is as defined in claim 2, is is a bond or an oxygen atom,P R3 is hydrogen, alkoxy of 1 to 4 carbon atoms or hydroxy and P is hydrogen and, when PR4 is hydrogen and, when R3 is alkoxy of 1 to 4 carbon atoms, RP4 additionally may be alkoxy of 1 to 4 carbon atoms, with the proviso that X is separated from the nitrogen atom of the 3 aminopropoxy chain by at least 2 carbon atoms, and RP2 has the significance indicated in claim 2 for R2. 4. The compound of any one of claims 1 to 3, which is 1 2 acetylisoindolin 4 yloxy 3 3,4 dimethoxy phenethylamino 2 propanol. 5. The compound of claim 2, wherein either R1 is i sopropyl and R2 is phenyl, or R1 is isopropyl and R2 is hydrogen, or R1 is 2 phenoxyethyl and R2 is hydrogen, or R1 is 2 methyl 4 phenylbut 2 yl and R2 is hydrogen, or R1 is 3 4 hydroxyphenyl 2 methylprop 2 yl and R2 is hydrogen, or R1 is tert butyl and R2 is methyl, or R1 is isopropyl and R2 is methyl, or R1 is isopropyl and R2 is ethoxy, or R1 is tert butyl and R2 is hydrogen, or R1 is 3,4 dimethoxyphenethyl and R2 is hydrogen, or R1 is 3,4 methylenedioxyphenethyl and R2 is hydrogen. 6. The compound of claim 2, wherein R1 is 3,4dimethoxyphenethyl, R2 is methyl and the hydroxy group in the 2 position of the 3 aminopropoxy side chain is esterified with either benzoyl or a tert butyl group. 7. A process for the production of a compound of claim 1, which comprises reacting a compound of formula F Het OCH2 RO F wherein Het is a heterocyclic nucleus which comprises anN carbonylisoindolinyl radical and the oxygen atom is attached directly to the 4 position of the isoindolinyl ring, and R is a group capable of reacting with a primary 0 or secondary amine to give a 2 amino l hydroxyethyl group, with an appropriate amine, and, where required, appropriately substituting the hydroxy group in the 2 position of the 3 aminopropoxy side chain. 8. A process for the production of a compound of claim 2, in free form or in salt form, which comprises reacting a compound of formula IIEMI22.1 wherein R2 is as defined in claim 2 and R is as defined 0 in claim 7 with a compound of formula III, R1 NH2 III wherein R1 is as defined in claim 2, and, where required, appropriately esterifying the 2 position of the 3 aminopropoxy side chain in the resulting compound of formula I. 9. A pharmaceutical composition comprising a compound of any one of claims 1 to 6 in free form or in pharmaceutically acceptable salt form, in association with a pharmaceutical carrier or diluent. 10.A compound of formula Het OCH2 RO or Het OH,wherein Het and R are as defined in claim 7. o 11. A compound of formula II,EMI23.1 wherein R2 is as defined in claim 2 and Ro is as defined in claim 7, or a compound of formula IV, EMI24.1 wherein R2 is as defined in claim 2.

## Description
3 AMINOPROPOXYARYL DERIVATIVES, THEIR PREPARATIONAND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM The present invention relates to 3 aminopropoxy aryl derivatives, their preparation and pharmaceutical compositions containing them. In particular the invention provides adrenergic blocking agents of the type having aEMI1.1 chain attached through the l oxygen atom directly to a heterocyclic nucleus, characterized in that the heterocyclic nucleus comprises an N carbonylisoindolinyl radical and the l oxygen atom of the side chain is attached directly to the 4 position of the isoindolinyl ring, hereinafter referred to as the compounds of the invention. In accordance with the invention, there are especially provided compounds of formula IEMI1.2 whereinR1 is alkyl of 3 to 7 carbon atoms or a groupEMI2.1 whereinA is alkylene of 2 to 5 carbon atoms,X is a bond,an oxygen or a sulfur atom, eitherR3 is hydrogen, halogen of atomic number of from 9 to 35, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms or hydroxy, andR4 is hydrogen and, when R3 is halogen of atomic number of from 9 to 35, R4 additionally may be halogen of atomic number of from 9 to 35 and, when R3 is alkoxy of 1 to 4 carbon atoms, R4 additionally may be alkoxy of 1 to 4 carbon atoms, orR3 and R4 together are methylenedioxy or ethylene dioxy, in the 2,3 or the 3,4 position, R5 is hydrogen and, when R3 and R4 both are alkoxy 3 4 of 1 to 4 carbon atoms, R5 additionally may be alkoxy of 1 to 4 carbon atoms, with the proviso that X is separated by at least 2 carbon atoms from the nitrogen atom of the 3 aminopropoxy side chain, and R2 is hydrogen, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms or phenyl unsubstituted or monosubstituted or independently disubstituted by alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, or halogen of atomic number of from 9 to 35, and physiologically acceptable hydrolyzable derivatives thereof having the hydroxy group in the 2 position of the 3 aminopropoxv side chain in esterified form. In the compounds of the invention the N carbonyl radical is preferably a group COR2 wherein R2 is as defined above. Physiologically hydrolyzable derivatives are those derivatives which under physiological conditions are split to the corresponding compounds having a hydroxy group in the 2 position of the 3 amino propoxy side chain. A group of derivatives in esterified form are e.g.the compounds of formula EEMI3.1 whereinR1 and R2 are as defined above andRe is alkyl of 1 to 12 carbon atoms, cycloalkyl of 3 to 7 carbon atoms, phenyl, phenylalkyl of 7 to 12 carbon atoms, phenyl or phenylalkyl of 7 to 12 carbon atoms monosubstituted in the phenyl ring by alkyl of 1 to 4 carbon atoms, or mono or indepen dently disubstituted in the phenyl ring by halogen of atomic number of from 9 to 35, or mono or independently di or independently trisubstituted in the phenyl ring by alkoxy of 1 to 4 carbon atoms.R1 preferably is a groupEMI4.1 Xpreferably is a bond or oxygen, especially a bona. R2 preferably is hydrogen or alkyl, especially alkyl.R3 preferably is hydrogen, hydroxy, alkoxy or together with R4 methylenedioxy or ethylenedioxy, especially alkoxy. R preferably is hydrogen, alkoxy or together 4 with R3 methylenedioxy or ethylenedioxy, especially hydrogen or alkoxy. R5 preferably is hydrogen. R prefer ably is alkyl or phenyl. Alternatively, R conveniently is e cycloalkyl, substituted phenyl or substituted or unsubstituted phenylalkyl. Alkyl except as indicated hereunder for R1 and R e and or alkoxy preferably are of 1 or 2, especially of 1 carbon atom . When R1 and or Re are alkyl, they preferably are of 3 to 5 carbon atoms and preferably are branched, especially in the position a to the nitrogen atom to which they are bound. Interesting alkyl groups R1 and or R are e.g. isopropyl, tert butyl e and 3 pentyl, especially tert butyl. Halogen preferably is bromine or chlorine, especially chlorine. Cycloalkyl preferably is of 5 or 6 carbon atoms. A and or the alkylene moiety of R when it is C phenylalkyl of more than 8 carbon atoms preferably is branched alkylene, especially in the position a to the nitrogen atom or carbonyl moiety to which it is bound, as e.g. in the group CEI CH3 CH2 , C CH3 2 CH2 or C CH3 2 CH2 2 . A especially is ethylene. R3 and R4 when bound together preferably are methylenedioxy. When R3 is not hydrogen, it preferably is in the para position. When R4 is not hydrogen, it preferably is in the meta position. When R5 is not hydrogen, it also preferably is in the meta position. When R3 andR4 together are methylenedioxy or ethylenedioxy, they preferably are in the meta and para positior. When R2 is monosubstituted phenyl and or when R is monosubsti C tuted phenyl or phenylalkyl, the substituent preferably is in the para position. When R2 is di substituted phenyl and or when R is di or trisubstituted C phenyl or phenylalkyl, the substituents preferably are in the meta and para positions. When R4 is not hydrogen, it preferably is identical to R3. When R5 is not hydrogen, it preferably is identical to R3 and R4. When R2 is disubstituted phenyl and or R is di or trisubstituted phenyl or phenylalkyl, C the substituents of the phenyl ring preferably are identical. A group of compounds of formula I are the compounds of formula IpEMI6.1 wherein PR1 is alkyl of 3 to 7 carbon atoms or a group EMI6.2 A is as defined above, P X is a bond or an oxygen atom, P R3 is hydrogen, alkoxy of 1 to 4 carbon atoms or hydroxy and P hydrogen and, when P R4 is hydrogen and, when R3 is alkoxy of 1 to 4 P carbon atoms, R4 additionally may be alkoxy of 1 to 4 carbon atoms, with the proviso that is separated from the nitrogen atom of the 3 aminopropoxy side chain by at least 2 carbon atoms, and PR2 has the significance indicated above for R2. In accordance with the invention, a compound of the invention may be obtained by reacting a compound of formula F Het OCH2, Ro F wherein Het is a heterocyclic nucleus which comprises .N carbonylisoindolinyl radical and the oxygen atom is attached directly to the 4 position of the isoindolinyl ring, and R is a group capable of reacting with a primary 0 or secondary amine to give a 2 amino l hydroxyethyl group, with a appropriate amine, and, where required, appropriately substituting the hydroxy group in the 2 position of the 3 aminopropoxy side chain. Especially, compounds of formula I and physiologically acceptable hydrolyzable derivatives thereof may be obtained by a process comprising reacting a compound of formula IIEMI8.1 wherein R and R2 are as defined above, with a compound of formula III R1 2 NH2 III wherein Rlis as defined above, and, where required, appropriately esterifying the 2 position of the 3 amino propoxy side chain in the resulting compound of formula I. The amination process may be effected in conventional manner for the production of analogous 3 amino 2 hydroxypropoxyaryl compounds.For example Ro may be a group of formulaEMI8.2 or a reactive derivative of this group, e.g.of formula Cli OH CH2Y, wherein Y is chlorine or bromine, or a group Ry SO2 O, wherein R is phenyl, tolyl or lower alkyl. Y is Cs y pecially chlorine. The reaction is preferably effected in an inert organic solvent, e.g. in an appropriate ether such as dioxane. Optionally an excess of the amine may be used as solvent. Alternatively the reaction may be effected in a fusion melt.Suitable reaction temperatures may be from about 20 to about 2000C, conveniently the reflux temperature of the reaction mixture when a solvent is present. The optional substitution of the 2hydroxy group in the side chain may be effected in conventional manner.For exsple,it may be esterified in manner knows for the production of analogous esters of 3 amino 2 hydroxypropoxyaryl compounds. When R3 is hydroxy, such esterification step is effected selectively in the 2 position of the 3 amino propoxy side chain, conveniently under tenporary protection of a such hydroxy group R3 in the form of e.g. a benzyloxy group and subsequent selective splitting of the protecting group, e.g. by hydrogenation. Free base forms of the compounds of the invention may be converted into salt forms in conventional manner and vice versa.Suitable acids for acid addition salt formation include maleic, malonic and fumaric acid. When R3 is hydroxy, salts may be formed with strong bases, e.g. sodium hydroxide. In the compounds of the invention, the carbon atom in 2 position of the 3 aminopropoxy side chain is asymmetrically substituted.The compounds may thus exist in the racemic form or in individual optical isomer form. The preferred optical isomer has the S config uration at the asymmetrically substituted carbon atom of the 3 aminopropoxy side chain. Individual optical isomer forms may be obtained in conventional manner, for example by using optically active starting materials or by fractional crystallisation using optically active acids. A compound of formula F forms part of the present invention, and may be obtained by introducing by O alkylation a group O CH2Ro into a compound of formula Het OH wherein Het is as defined above. In particular,a compound of formula II may be obtained by introducing by O alkylation a group OCH2 R0 into a compound of formula IVEMI11.1 wherein R2 is as defined above. The compounds of formulaIV are preferably reacted in anionic form. A compound of formula Het OH, wherein Het is as defined above, forms part of the present invention and may be obtained by introducing a carbonyl group into the 2 position of the corresponding isoindolinol. Similarly a compound of formula IV may be obtained by introducing a group COR2 in the 2 position of 4 isoindolinol. Insofar as the preparation of any particular starting material is not particularly described, this may be effected in conventional manner. In the following examples all temperatures are in degrees Centigrade and are uncorrected. Example 1 1 2 acetylisoindolin 4 yloxy 3 3,4 dimethoxyphenethylamino 2 propanol 2,5 g 2 acetyl 4 2,3 epoxypropoxy isoindoline and 1 ml 3,4 dimethoxyphenethylamine dissolved in 50 ml dioxane are kept at 1300 in an autoclave for 20 hours. The solvent is then evaporated, the residue dissolved in methylene chloride and extracted with 1N tartaric acid.The aqueous phase is then separated, made alkaline with dilute sodium hydroxide solution, and extracted with methylene chloride. The title compound is formed M.P. of the hydrogen maleate form 177 178 from methanol ether . The starting material 2 acetyl 4 2,3 epoxypropoxy isoindoline is obtained as follows a Reaction of acetyl chloride with isoindolin 4 ol hydrochloride in pyridine at 250 yields 2 acetyl isoindolin 4 ol M.P. 256 258 dec. from methanol ether .b Reaction at 1000 of 2 acetylisoindolin 4 ol with epichlorhydrin in excess and in presence of catalytic amounts of piperidine yields 2 acetyl 4 2,3 epoxypropoxy isoindoline M.P. 100 1020 from methylene chloride ether . Example 2 1 2 acetylisoindolin 4 yloxy 3 3,4 dimethoxyphenethylamino 2 propanol benzoate 2.0 g of benzoic acid and 1.0 g of l 2 acetyl iso indolin 4 yloxy 3 3,4 dimethoxyphenethylamino 2 propanol in 10 ml of chloroform are reacted dropwise at Oo with 0.65 g of benzoic anhydride in 10 ml of chloroform. After 1 hour at 500, an excess of a 2N sodium hydroxide solution is added and the reaction mixture is extracted thrice with methylene chloride, the combined organic phases are dried over MgS04, filtered and concentrated. The title compound is formed M.P. of the hydrogen fumarate form 153 1550 from methanol ether . From the appropriate compound of formula II, wherein R is CH OH CH2Cl, and the appropriate compound 0 of formula III the following compounds of formula I may be obtained in analogous manner to Example 1 EMI14.1 tb Ex.No SEP R1 SEP R2 SEP M.P. tb SEP 3 SEP isopropyl SEP phenyl SEP ch SEP 206 207 SEP tb SEP 4 SEP isopropyl SEP hydrogen SEP hfu SEP 156 158 SEP tb SEP 5 SEP 2 pher oxyethyl SEP hydrogen SEP hfu SEP 176 1780. SEP tb SEP 6 SEP 2 methyl 4 phenylbut SEP hydrogen SEP bfu SEP 213 214 SEP tb SEP 2 yl tb SEP 7 SEP 3 4 hydroxyphenyl 2 SEP hydrogen SEP bfu SEP 198 200 SEP SEP tb SEP methylprop 2 yl tb SEP 8 SEP tert butyl SEP methyl SEP hfu SEP 199 201 SEP tb SEP 9 SEP isopropyl SEP methyl SEP bfu SEP 166 170 SEP tb SEP 10 SEP isopropyl SEP ethoxy SEP b SEP 127 128 SEP tb SEP 11 SEP tert butyl SEP hydrogen SEP bfu SEP 189 191 SEP tb SEP 12 SEP 3,4 dimethoxyphenethyl SEP hydrogen SEP b SEP 148 150 SEP tb SEP 13 SEP 3,4 methylenedioxyphen SEP hydrogen SEP hfu SEP 153 155 SEP tb SEP ethyl tb SEP b SEP SEP free SEP form tb SEP bfu SEP SEP biLbaseJfumarate SEP form tb SEP ch SEP SEP hydrochloride SEP form tb SEP hfu SEP SEP hydrogen SEP fumarate SEP form tb From the appropriate compound of formula I, the following compound of formula E may be obtained in analogous manner toExample 2 EMI14.2 tb Ex.No. SEP R1 SEP 2 SEP M.P. tb SEP e tb SEP I tb 14 SEP 3,4 dimethoxy SEP methyl SEP tert butyl SEP oil tb SEP phenethyl tb The compounds of the invention exhibit pharmacological activity. In particular, the compounds possess ss adrenergic blocking activity, as indicated by standard tests. For example, in the isolated, spontaneously beating guinea pig atrium method of K. Saameli, Helv.Physiol. Acta 25 1967 CR 219 CR 221 inhibition of the positive inotropic effect of adrenaline is observed at a bath concentration of about 10 5 to about lo 3 mg l. The compounds are therefore indicated for use as ss adrenergic blocking agents, e.g. for the prophylaxis and treatment of hypertension, of coronary diseases, such as Angina pectoris, of conditions resulting from sympathetic overstimulation, such as nervous heart ailments of myocardial infarct, for interval migraine treatment, and for the treatment of glaucoma, thyreo toxicosis and arrhythmias. The compounds also exhibit a adrenergic blocking activity, as indicated by standard tests. For example, the inhibition of a adrenoceptors may be observed in isolated spiral strips of the Vena femoralis of dogs E. Muller Schweinitzer and E. Sttirmer, Br.J. Pharmacol. 1974 51, 441 446 at a bath concentration of from about 10 7 M to about 10 5 M. The compounds are therefore indicated for use as a adrenergic blocking agents, e.g. for the prophylaxis and treatment of disorders related to a paralysis of intestine motility, such as paralytic ileus. It will be appreciated that it may be necessary to convert a compound having a substituted hydroxy group in the 2 position of the 3 aminopropoxy side chain to the corresponding free hydroxy compound prior to carrying out the tests indicated above for showing a and 3 adre nergic blocking activity. An indicated daily dose is from about 5 mg to about 500 mg, conveniently given in divided doses 2 to 4 times a day in unit dosage form containing from about 1.25 mg to about 250 mg, or in sustained release form.The compounds wherein a groupEMI16.1 is attached to the nitrogen atom of the 3 aminopropoxy side chain are especially interesting as cardioselective blocking agents. The compounds of Examples 1 and 12 exhibit particularly interesting activity as 3 blockers. In general, the 2 S optical isomers of the com pounds are more active than the 2 R optical isomers as blocking agents. The compounds may he administered in pharmaceu tically acceptable salt form. Such salt forms exhibit the same order of activity as the free forms and are readily prepared in conventional manner. The present invention also provides a pharmaceutical composition comprising a compound of the invention, in free form or in pharmaceutically acceptable salt form, in association with a pharmaceutical carrier or diluent.Such compositions may be in the form of, for example, a solution or a tablet.